Vishal C Patel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/773483/publications.pdf

Version: 2024-02-01

58 papers	2,355 citations	304743 22 h-index	243625 44 g-index
59 all docs	59 docs citations	59 times ranked	3288 citing authors

#	Article	IF	Citations
1	Rifaximin-Î± reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. Journal of Hepatology, 2022, 76, 332-342.	3.7	79
2	Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease. Thrombosis and Haemostasis, 2022, 122, 1006-1016.	3.4	16
3	Aberrant hepatic trafficking of gutâ€derived T cells is not specific to primary sclerosing cholangitis. Hepatology, 2022, 75, 518-530.	7.3	21
4	Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices. PLoS ONE, 2022, 17, e0263288.	2.5	4
5	Images of the month 1: Histoacryl glue embolisation to the right ventricle following treatment for gastric varices. Clinical Medicine, 2022, 22, 163-164.	1.9	2
6	Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates. Liver International, 2022, 42, 435-443.	3.9	8
7	Global hemostatic status in patients with acuteâ€onâ€chronic liver failure and septics without underlying liver disease. Journal of Thrombosis and Haemostasis, 2021, 19, 85-95.	3.8	38
8	P225â€...Partial splenic artery embolisation for portal hypertension â€“ a single centre experience. , 2021, , .		0
9	Hemostatic balance in acuteâ€onâ€chronic liver failure. Journal of Thrombosis and Haemostasis, 2021, 19, 869-870.	3.8	1
10	Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acuteâ€onâ€Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acidâ€“Dependent Monocyte Activation. Hepatology, 2021, 74, 907-925.	7.3	28
11	The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury. Frontiers in Cell and Developmental Biology, 2021, 9, 668459.	3.7	1
12	Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acuteâ€onâ€Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival. Hepatology, 2020, 71, 1381-1390.	7.3	63
13	Antimicrobial resistance in chronic liver disease. Hepatology International, 2020, 14, 24-34.	4.2	20
14	Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis. JHEP Reports, 2020, 2, 100151.	4.9	26
15	Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay. Journal of Thrombosis and Haemostasis, 2020, 18, 834-843.	3.8	22
16	Modulating the gutâ€“liver axis and the pivotal role of the faecal microbiome in cirrhosis. Clinical Medicine, 2020, 20, 493-500.	1.9	6
17	FRI-099-PD-1+ monocytes and macrophages contribute to impaired microbial clearance following acute liver failure. Journal of Hepatology, 2019, 70, e430-e431.	3.7	0
18	Plasma levels of circulating DNA are associated with outcome, but not with activation of coagulation in decompensated cirrhosis and ACLF. JHEP Reports, 2019, 1, 179-187.	4.9	21

#	Article	IF	Citations
19	PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis. Journal of Hepatology, 2019, 70, e108.	3.7	1
20	THU-055-Improved stratification of liver failure syndromes using broad-panel bile acid LCMS phenotyping demonstrates novel pathways of dysregulation in tertiary bile acids in acute-on-chronic liver failure. Journal of Hepatology, 2019, 70, e184-e185.	3.7	0
21	PS-144-Autotaxin mediates lipid dysregulation in acute-on-chronic liver failure, promoting persistence of systemic inflammation via lysophosphatidic acid-mediated monocyte activation. Journal of Hepatology, 2019, 70, e91-e92.	3.7	0
22	Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and allâ€cause admissions in patients on the liver transplant waiting list. Alimentary Pharmacology and Therapeutics, 2019, 50, 435-441.	3.7	43
23	THU-052-Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK+ immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure. Journal of Hepatology, 2019, 70, e183.	3.7	1
24	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial. BMJ Open, 2019, 9, e023518.	1.9	27
25	P: 12â€ƒPROFIT: PROspective, Randomised Placebo-controlled Feasibility Trial of Faecal Microbiota Transplantation in Cirrhosis Interim Analysis. American Journal of Gastroenterology, 2019, 114, S5-S7.	0.4	2
26	P: 71â€ƒFaecal Cytokine Profiling Provides Novel Insights Into Intestinal Barrier Disruption and Bacterial Translocation in Acute Decompensation of Cirrhosis. American Journal of Gastroenterology, 2019, 114, S36-S37.	0.4	1
27	Plateletâ€leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion. Alimentary Pharmacology and Therapeutics, 2018, 47, 1375-1386.	3.7	17
28	MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure. Gut, 2018, 67, 333-347.	12.1	150
29	CD14⁺CD15^{â^'}HLA-DR^{â^'} myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut, 2018, 67, 1155-1167.	12.1	111
30	Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 192-202.	3.7	174
31	Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. Journal of Critical Care, 2018, 43, 54-60.	2.2	87
32	Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. Gut, 2018, 67, 918-930.	12.1	106
33	PTH-106â€…Plasma S100A8/A9: a novel mechanistic biomarker in innate immune activation in acute-on-chronic liver failure. , 2018, , .		2
34	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. Journal of Clinical Apheresis, 2018, 33, 638-644.	1.3	12
35	In vitro efficacy of proâ€and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. Liver International, 2018, 38, 1988-1996.	3.9	35
36	High-Speed Quantitative UPLC-MS Analysis of Multiple Amines in Human Plasma and Serum via Precolumn Derivatization with 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate: Application to Acetaminophen-Induced Liver Failure. Analytical Chemistry, 2017, 89, 2478-2487.	6.5	78

#	Article	IF	Citations
37	Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure. Critical Care Medicine, 2016, 44, 43-53.	0.9	24
38	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximinâ€Î±. Liver International, 2016, 36, 1295-1303.	3.9	46
39	The Formation of Activated Platelet-Complexed Leukocytes is Augmented in Cirrhosis and Enhanced by Platelet Transfusion. Journal of Hepatology, 2016, 64, S526-S527.	3.7	0
40	Mer Tyrosine Kinase Regulates the Activation of Myeloid Cells and Innate Immune Responses in Acute-on-Chronic Liver Failure. Journal of Hepatology, 2016, 64, S143.	3.7	1
41	Altered Gut Microbial Profile is a Proponent of Bacterial Translocation in Acute-on-Chronic Liver Failure. Journal of Hepatology, 2016, 64, S453-S454.	3.7	0
42	Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. Journal of Hepatology, 2016, 64, 1058-1067.	3.7	77
43	High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. Journal of Hepatology, 2016, 64, 69-78.	3.7	466
44	Clinical science workshop: targeting the gut-liver-brain axis. Metabolic Brain Disease, 2016, 31, 1327-1337.	2.9	23
45	P1119 : Elevated levels of circulating bacterial DNA in alcoholic hepatitis identifies patients who will not respond to corticosteroid. Journal of Hepatology, 2015, 62, S770.	3.7	1
46	P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure. Journal of Hepatology, 2015, 62, S324.	3.7	0
47	Salivary microbiotaâ€immune profiling in cirrhosis: Could this be the noninvasive strategy that will revolutionize prognostication in hepatology?. Hepatology, 2015, 62, 1001-1003.	7.3	11
48	P0168 : The impact on hospital resource utilisation of Rifaximin-alpha for hepatic encephalopathy in routine clinical practice: Real world data from seven UK liver centres. Journal of Hepatology, 2015, 62, S366.	3.7	0
49	Patients With Acute-on-Chronic Liver Failure Have Increased Numbers of Regulatory Immune Cells Expressing the Receptor Tyrosine Kinase MERTK. Gastroenterology, 2015, 148, 603-615.e14.	1.3	207
50	Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failureâ€"Sequential Organ Failure Scoring System. Clinical Gastroenterology and Hepatology, 2015, 13, 1353-1360.e8.	4.4	91
51	O106 : Therapeutic plasma exchange modulates innate immune activation and improves outcome in patients with acute liver failure. Journal of Hepatology, 2015, 62, S246-S247.	3.7	0
52	P1329 : A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy (â€˜RIFSYSâ€™). Journal of Hepatology, 2015, 62, S854.	3.7	0
53	Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. Immunotherapy, 2015, 7, 641-654.	2.0	32
54	588 The Impact on Hospital Resource Utilization of Rifaximin-Î± for Hepatic Encephalopathy in Routine Clinical Practice: Real World Data From Seven UK Liver Centres. Gastroenterology, 2015, 148, S-988.	1.3	0

#	Article	IF	Citations
55	Bile Acid Profiling and Quantification in Biofluids Using Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. Analytical Chemistry, 2015, 87, 9662-9670.	6.5	166
56	Liver transplantation: patient selection, organ allocation, and outcomes. , 2015, , 201-210.		0
57	OC-029â€…Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience. Gut, 2014, 63, A14.2-A15.	12.1	3
58	Diabetes and the gastrointestinal tract. Medicine, 2011, 39, 288-292.	0.4	4